TARS Tarsus Pharmaceuticals
- 37.030
- +0.180+0.49%
- 36.040
- -0.990-2.67%
Tarsus Pharmaceuticals News
Goldman Sachs Maintains Neutral on Tarsus Pharmaceuticals, Raises Price Target to $30
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $57
Oppenheimer Reiterates Outperform on Tarsus Pharmaceuticals, Raises Price Target to $59
Tarsus Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Irhythm Technologies (IRTC), Tarsus Pharmaceuticals (TARS) and Springworks Therapeutics (SWTX)
Buy Rating Affirmed: Tarsus Pharmaceuticals' Strong Q4 and Robust Pipeline Fuel Upward Price Revision
Barclays Sticks to Its Buy Rating for Tarsus Pharmaceuticals (TARS)
Buy Rating Affirmed for Tarsus Pharmaceuticals Amid Promising TP-05 Lyme Disease Prophylactic Trial Results
Promising Pipeline and Market Entry Fuel Buy Rating for Tarsus Pharmaceuticals
Goldman Sachs Initiates Coverage On Tarsus Pharmaceuticals With Neutral Rating, Announces Price Target of $19
Tarsus Pharmaceuticals Analyst Ratings
Oppenheimer Keeps Their Buy Rating on Tarsus Pharmaceuticals (TARS)
Promising Market Performance and Strong Sales Projection Uphold Buy Rating for Tarsus Pharmaceuticals
Analysts' Opinions Are Mixed on These Healthcare Stocks: Knight Therapeutics (OtherKHTRF), Tarsus Pharmaceuticals (TARS) and Illumina (ILMN)
HC Wainwright & Co. Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $50
Tarsus Pharmaceuticals Analyst Ratings
Oppenheimer Remains a Buy on Tarsus Pharmaceuticals (TARS)
Analysts Conflicted on These Healthcare Names: Nurix Therapeutics (NRIX), Tarsus Pharmaceuticals (TARS) and TG Therapeutics (TGTX)
Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $49
Tarsus Pharmaceuticals Analyst Ratings
Analysis
Price Target
No Data
